SCHEMBL7185151

SCHEMBL7185151

CCOP(=O)(CCCc1ccccc1)Cc1ccc(C(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 6/20 0.47
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
RARA P10276 1/20 0.45
MAPT P10636 1/20 0.45
MTOR P42345 1/20 0.45
KMT2A Q03164 1/20 0.45
PTGER1 P34995 1/20 0.44
PTGER4 P35408 1/20 0.44
PTGER3 P43115 1/20 0.44
PTGER2 P43116 1/20 0.44
HDAC8 Q9BY41 1/20 0.43
CETP P11597 3/20 0.43
HDAC1 Q13547 1/20 0.43
TRPV1 Q8NER1 1/20 0.42
PLA2G4B P0C869 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188250 0.87 KMT2A (0.49) ALDH1A1MEN1MAPTKMT2ACETP
SCHEMBL3486531 0.81 RARB (0.54) RARBALDH1A1MEN1RARAMAPT
SCHEMBL7519426 0.81 PRSS1 (0.44)
SCHEMBL11513875 0.80 HDAC3 (0.45) MEN1MAPTKMT2AHDAC8CETP
SCHEMBL8347665 0.79 CETP (0.49) CETP
SCHEMBL340397 0.76 CETP (0.43) HDAC8CETPHDAC1
SCHEMBL7379497 0.76 CETP (0.47) ALDH1A1MAPTKMT2AHDAC8CETP
SCHEMBL563856 0.75 NPSR1 (0.50) MEN1KMT2ACETP
SCHEMBL8668415 0.75 ALDH1A1 (0.50) RARBALDH1A1MEN1RARAMAPT
SCHEMBL10890173 0.75 MAPT (0.51) MAPTHDAC8CETPHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583177-B2 Amidinophenol derivatives as leukotriene B4 (LTB4)antagonists, phospholipase A2 inhibitors, and trypsin inhibitors. ONO PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed
US-20020128315-A1 Leukotriene B4 antagonist compounds and method for treatment NAKAI HISAO (JP) 2002-09-12 US disclosed
US-6262114-B1 NOVEL AMIDINOPHENOL DERIVATIVES; INHIBITORS OF PHOSPHOLIPASE A2 AND/OR TRYPSIN ONO PHARMACEUTICAL CO., LTD. (JP) 2001-07-17 US disclosed
EP-0703216-B1 Amidinophenol derivatives as protease inhibitors ONO PHARMACEUTICAL CO (JP) 1999-04-07 EP disclosed
EP-0703216-A1 Amidinophenol derivatives as protease inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1996-03-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128315-A1 Leukotriene B4 antagonist compounds and method for treatment LTB4R2, LTB4R, LTA4H RARB 1773/4885ALDH1A1 1930/4885MEN1 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.